Boston Scientific Corp (WBO:BSXC)
€ 68.5 1 (1.48%) Market Cap: 100.27 Bil Enterprise Value: 108.32 Bil PE Ratio: 61.71 PB Ratio: 5.42 GF Score: 73/100

Boston Scientific Corp Investor Update at Transcatheter Cardiovascular Therapeutics 2020 Transcript

Oct 15, 2020 / 05:00PM GMT
Release Date Price: €34.58 (+0.09%)
Operator

Good day, and welcome to the Boston Scientific Update at TCT Conference Call. (Operator Instructions) Please note, this event is being recorded.

I would now like to turn the conference over to Susie Lisa, Vice President of Investor Relations. Please go ahead.

Susan Vissers Lisa
Boston Scientific Corporation - VP of IR

Thank you very much, and thank you, everyone, for joining us for the TCT 2020 Investor Update. I am very pleased to have with us this morning leaders from our Peripheral Interventions and Interventional Cardiology team.

We'll kick things off with PI with Jeff Mirviss, our Executive Vice President and President of Peripheral Interventions; and then Dr. Michael Jaff, our Chief Medical Officer and VP of Clinical Affairs, Innovation and Technology for PI. Then we'll follow with Joe Fitzgerald, our Executive Vice President and President of Interventional Cardiology; and Dr. Ian Meredith, our Executive Vice President and Global Chief Medical Officer.

Before we begin, the usual safe harbors apply. We will be making forward

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot